Non-small cell lung cancer (NSCLC) remains a predominant cause of cancer-related mortality worldwide. In recent years, immune checkpoint inhibitors (ICIs) have emerged as a transformative therapeutic ...

A new drug strategy that regulates the tumor immune microenvironment may transform a tumor that resists immunotherapy into a ...

A novel test developed by Duke-NUS researchers enables real-time monitoring of T cells that have been engineered to ...

A breast cancer vaccine could be closer to reality, according to Cleveland Clinic, as its researchers have announced some encouraging results. Researchers and doctors weigh in.

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.

By exploiting the genetic variation in cancer cells, an already approved cancer drug demonstrated enhanced effects against cancer cells in specific patient groups, according to a new study. The ...

The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...

UCSF researchers develop customizable SNIPR sensors that activate engineered cells only near tumors, promising precise cancer ...

Patients with lung cancer who have never smoked are usually diagnosed too late for curative treatment. Pam Dalrymple, ...

Immunology is the study of the immune system and its defense mechanisms, and immuno-oncology is when cancer patients are ...

In a small subset of those patients, the combination resulted in a strong response with tumor shrinkage and no disease ...

ALL patients who received Aucatzyl immunotherapy, made from their own T cells, experienced complete remission within three ...